Navigation Links
Evotec AG: R&D Update on 16 October 2007 Live on the Internet
Date:10/9/2007

HAMBURG, Germany and OXFORD, England, October 9 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) is going to hold an R&D Update in London on Tuesday 16 October 2007 at 13.00 pm BST (14.00 pm CET, 08.00 am US time East Coast) which will be broadcast live on the internet.

Jorn Aldag, (President & Chief Executive Officer), Dr John Kemp, (Chief Research & Development Officer) and Dr Tim Tasker, (EVP Clinical Development) will provide an update on the status and development plans for Evotec's Clinical Programs and Discovery Projects. In addition, we are delighted to announce that Dr Michael G Kelly, (SVP Research & Development) at Renovis, will present the Renovis Pipeline Programs.

To join the audio webcast and to access the presentation slides you will find a link on our home page http://www.evotec.com shortly before the event.

For those who prefer to listen to the presentation via phone, please dial:

From Europe: +49(0)69-5007-1308 (Germany)

+44(0)20-7806-1956 (UK)

From the US: +1-718-354-1388

Pass Code: 2793143

The on-demand version of the webcast will be available on our website: http://www.evotec.com - Investors - Webcasts.

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.

In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. Evotec has three programmes in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease and/or pain, and EVT 302, a MAO-B inhibitor in development for smoking cessation.

On 19 September 2007, Evotec announced that it has entered into a definitive agreement under which Evotec will acquire Renovis, a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of pain and inflammatory diseases.

Contact:

Evotec AG

Anne Hennecke

SVP, Investor Relations & Corporate Communications

Phone: +49(0)40-56081-286

Fax: +49(0)40-56081-333

E-Mail: anne.hennecke@evotec.com


'/>"/>
SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Merge unveils updated medical imaging software
2. Merge announces sofware updates, upcoming acquisition
3. Tech Digest: Merge eMed product updates; Renaissance Learning 3rd qtr results
4. Solinus updates MailFoundry anti-spam hardware, switching to Linux
5. Dane County mapping software updated, available to public
6. Wingra Technologies updates data migration software
7. Firstlogics mailing-address update system gains Postal Service certification
8. Lands End Debuts Updated Virtual Model
9. Internet-enabled niche markets take center stage
10. Emergence of Internet video is changing the regulatory landscape
11. Viewing the Internet as a free-for-all can be costly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
Breaking Biology News(10 mins):